Other Potential Therapeutic Targets in Thyroid Orbitopathy

Author(s): Terry J. Smith

Journal Name: Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization)
Formerly Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents

Volume 11 , Issue 2 , 2011


Abstract:

Graves disease comprises a syndrome involving the thyroid, orbit and skin. The unifying components that tie together these anatomically diffuse manifestations remains uncertain as do the genetic and environmental factors initiating and propagating disease. The orbital process, termed thyroid- associated ophthalmopathy or Graves orbitopathy, is not effectively managed because we do not yet understand enough about its pathogenesis to develop specific and safe therapeutic agents. Moreover, we lack complete and robust pre-clinical models of Graves disease. In this brief review, I will attempt to discuss the potential targets to which new agents might be developed and others that are already available and could be utilized in clinical trails. The wide array of biological agents recently introduced to the marketplace and those currently under development offer an opportunity to identify productive treatment strategies for this vexing disease.

Keywords: Graves' disease, immunomodulation, lymphocytes, cytokines, autoimmune, orbit, inflammation, ophthalmopathy, immunoglobulins, thyrotropin receptor, insulin-like growth factor receptor-1

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 2
Year: 2011
Published on: 01 March, 2012
Page: [112 - 117]
Pages: 6
DOI: 10.2174/187152211795495661
Price: $65

Article Metrics

PDF: 7